Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

S.A. Prabowo, M.I. Groschel, E.D. Schmidt, A. Skrahina, T. Mihaescu, S. Hasturk, R. Mitrofanov, E. Pimkina, I. Visontai, B. De Jong, J.L. Stanford, P.J. Cardona, S.H. Kaufmann, T.S. van der Werf

Research output: Contribution to journalA1: Web of Science-article

Abstract

Tuberculosis (TB) has scourged humankind for millennia, and latent infection affects nearly one-third of today's world population. The emergence of multidrug-resistant (MDR)-TB is a major global threat and reflects treatment failure of drug-sensitive disease. MDR-TB management is a burden for patients and society; success rates are unacceptably low with prolonged treatment duration. Mycobacterium tuberculosis (Mtb) possesses the ability to transform into a dormant state in which it can persist in the face of antimicrobial treatment and host defense. This sub-population of persisters is largely responsible for lengthy and difficult treatment. Targeting persistent bacilli could eventually improve the treatment success rate (currently 50-65 %) and shorten duration of treatment. A subset of therapies in the pipeline, termed therapeutic vaccines, use the host immune response to attack Mtb. The historical occurrence of an exacerbated host response has resulted in a negative perception of therapeutic vaccines. Thus, a renewed concept of immunotherapy is needed. We review current perspectives of immunotherapy in MDR-TB based on the knowledge of TB immunology and briefly discuss the profiles of several therapeutic vaccine products.
Original languageEnglish
JournalMedical Microbiology and Immunology
Volume202
Issue number2
Pages (from-to)95-104
Number of pages10
ISSN0300-8584
DOIs
Publication statusPublished - 2013

Keywords

  • Bacterial diseases
  • Tuberculosis
  • Mycobacterium tuberculosis
  • Control
  • Multidrug resistance
  • Vaccines
  • Therapeutics
  • Immunotherapy
  • Review of the literature

Fingerprint Dive into the research topics of 'Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines'. Together they form a unique fingerprint.

Cite this